Foamix pharmaceuticals ltd. (FOMX)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS FOR THE YEAR

-95,178

-71,436

-63,755

-63,390

-74,163

-77,446

-79,549

-77,308

-65,715

0

0

0

Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

350

332

316

309

319

311

296

263

221

0

0

0

Loss from sale and disposal of fixed assets

-

-

-

-

-44

-45

-66

-68

-134

0

0

0

Changes in marketable securities and bank deposits, net

357

233

290

23

-201

-182

-98

39

-97

0

0

0

Changes in accrued liability for employee severance benefits, net of retirement fund profit

57

39

31

-5

-70

-49

-56

-69

57

0

0

0

Share-based compensation

4,895

4,782

4,703

4,516

5,320

5,627

5,633

5,154

4,166

0

0

0

Non-cash finance expenses (income), net

-140

-108

-22

-65

-43

-1

-39

-1

47

0

0

0

Changes in operating asset and liabilities:
Decrease (increase) in trade and other receivables

-373

-1,534

340

1,095

308

986

176

-2,794

-1,915

0

0

0

Decrease (increase) in other non-current assets

-

-

-

0

-

-

-

-

-

-

-

-

Increase in accounts payable and accruals

18,053

3,216

-1,938

-2,206

238

914

3,741

3,827

5,003

0

0

0

Net cash used in operating activities

-73,394

-62,046

-61,503

-62,113

-68,664

-70,399

-68,916

-64,317

-53,177

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets

1,058

1,020

693

583

567

767

1,072

1,360

1,518

0

0

0

Investment in bank deposits

-

-

0

38,500

-

-

36,500

12,293

17,000

0

0

0

Investment in marketable securities

-

-

-

-

38,652

5,660

20,938

20,938

22,839

0

0

0

Proceeds from sale and maturity of marketable securities and bank deposits

87,851

84,872

79,317

52,689

66,454

88,020

76,308

85,448

79,079

0

0

0

Net cash provided by (used in) investing activities

41,869

-13,265

13,446

-24,024

-11,755

45,110

17,831

50,890

37,755

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options and issuance of shares under the employee shares purchase plan

365

0

0

0

-

-

-

-

161

0

0

0

Payments in respect of bank borrowings

-

-

-

-

-

-

-

-

21

0

0

0

Net cash provided by financing activities

47,950

0

0

0

-

-

-

-

140

0

0

0

INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

16,425

-47,345

27,354

6,253

11,955

0

0

0

-

-

-

-

EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH

41

2

29

-29

-43

0

0

0

-

-

-

-

INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

-

-

-

-

-

-

0

0

0

EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

-

-

-

-

-

-

0

0

0

SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Cashless exercise of warrants and restricted share units

11

11

11

12

11

0

0

0

-

-

-

-

Property and equipment purchases included in accounts payable and accruals

-

-

-

-

-

-

-

0

-

-

0

0

Additions to operating lease right of use assets and liabilities

1,175

0

0

0

-

-

-

-

-

-

-

-

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest received

1,359

1,514

1,334

1,096

1,173

1,066

986

1,415

1,209

0

0

0

Interest paid

-

-

-

-

-

-

-

-

-

0

0

0